Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ravuconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 13/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 12/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.54 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.54 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.54 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ravuconazole SCHEMBL939025 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Ravuconazole SCHEMBL30994710 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Ravuconazole SCHEMBL939026 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Ravuconazole SCHEMBL13169577 | 1.00 | CYP3A4 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Isavuconazole SCHEMBL939036 | 0.94 | ABCG2 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Isavuconazole SCHEMBL31454343 | 0.94 | ABCG2 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Isavuconazole SCHEMBL13649107 | 0.94 | ABCG2 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Isavuconazole SCHEMBL30524137 | 0.94 | ABCG2 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Isavuconazole SCHEMBL21665461 | 0.94 | ABCG2 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 | |
| Isavuconazole SCHEMBL939038 | 0.94 | ABCG2 (1.00) | CYP3A4KCNH2ABCG2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324728-B2 | Dosing regimens for the treatment of fungal infections | SEREN PHARMACEUTICALS INC. (JP) | 2022-05-10 | — | — | US | disclosed |
| US-20200316033-A1 | DOSING REGIMENS FOR THE TREATMENT OF FUNGAL INFECTIONS | SEREN PHARMACEUTICALS INC. (JP) | 2020-10-08 | — | — | US | disclosed |
| EP-1345915-B1 | IMPROVED PROCESS FOR THE PREPARATION OF WATER-SOLUBLE O-PHOSPHONOOXYMETHYL PRODRUGS | EISAI CO LTD (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324728-B2 | Dosing regimens for the treatment of fungal infections | DPM1, ERG28, CYP51A1 | CYP3A4 29/4885KCNH2 2795/4885ABCG2 880/4885 |
| US-20200316033-A1 | DOSING REGIMENS FOR THE TREATMENT OF FUNGAL INFECTIONS | DPM1, ERG28, CYP51A1 | CYP3A4 29/4885KCNH2 2795/4885ABCG2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.